title: A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
abstract: The aim of the study was to compare reductions in uric acid (UA), length of stay (LOS), and hospitalization costs in patients with tumor lysis syndrome (TLS) treated with rasburicase or allopurinol.
  
  
  
  This retrospective study of administrative data included hospitalized pediatric and adult patients who had clinical or laboratory TLS and received rasburicase or allopurinol. Each rasburicase-treated patient was propensity score-matched with 4 allopurinol-treated patients. Mean changes in UA within ≤ 2 days of treatment initiation were determined. Economic outcomes included mean number of days in the intensive care unit (ICU), total LOS, costs/hospitalization, and costs/percentage change in UA.
  
  
  
  Twenty-six rasburicase-treated patients were matched with 104 allopurinol-treated patients. Reduction in plasma UA was 5.3 mg/dL greater for patients treated with rasburicase than for patients treated with allopurinol (P < .0001). Length of ICU stay was 2.5 days less for patients treated with rasburicase than for patients treated with allopurinol (P < .0001), and total LOS was 5 days less for patients treated with rasburicase than for patients treated with allopurinol (P = .02). Total costs per patient were $20,038 lower for patients treated with rasburicase than for patients treated with allopurinol (P < .02). Cost per percentage UA reduction was also lower for patients treated with rasburicase versus patients treated with allopurinol ($3899 vs. $16,894; P < .001).
  
  
  
  In this analysis of TLS patients who received care in real-world settings, rasburicase versus allopurinol was significantly more effective in treating hyperuricemia and was associated with significantly shorter ICU and overall hospital stays and lower total inpatient costs.
authors.affiliation: Departments of Pediatrics, Medicine, Pathology, Microbiology and Immunology, and Cell Biology and Anatomy, Maria Fareri Children's Hospital at Westchester Medical Center, New York Medical College, Valhalla, NY. Electronic address: mitchell_cairo@nymc.edu.
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Cairo
authors.affiliation: Sanofi US, Inc, Bridgewater, NJ.
authors.forename: Stephen
authors.initials: S
authors.lastname: Thompson
authors.affiliation: Sanofi US, Inc, Bridgewater, NJ.
authors.forename: Krishna
authors.initials: K
authors.lastname: Tangirala
authors.affiliation: Xcenda, Palm Harbor, FL.
authors.forename: Michael T
authors.initials: MT
authors.lastname: Eaddy
mesh_terms: D000493:Allopurinol / Q000191:economics* / Q000627:therapeutic use; D005260:Female; D006074:Gout Suppressants / Q000191:economics* / Q000627:therapeutic use; D006760:Hospitalization / Q000191:economics*; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy / Q000191:economics; D007902:Length of Stay / Q000191:economics*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015275:Tumor Lysis Syndrome / Q000188:drug therapy / Q000191:economics*; D014503:Urate Oxidase / Q000191:economics* / Q000627:therapeutic use; D014527:Uric Acid / Q000378:metabolism
chemical_list: D006074:Gout Suppressants; C469709:rasburicase; D014527:Uric Acid; D000493:Allopurinol; D014503:Urate Oxidase
keywords: Costs; Elitek; Hematologic cancer; Oncologic complications; Pediatrics and adults